Wijngaards G
Thromb Haemost. 1979 May 25;41(3):590-600.
The assay of plasminogen activator activities on fibrin plates was re-evaluated with special reference to fibrinolysis inhibitors present in samples and in fibrin plates. The nature, action and stability of inhibiting material were studied in tissue with considerable differences in activator and inhibitor contents: human lung, liver and placenta. Extracts were tested for inhibitory capacity against purified human uterine tissue plasminogen activator, urokinase and plasmin of fibrin plates prepared from different grades of fibrinogen and fibrin. The tissue extracts inhibited fibrinolysis on fibrin plates to varying degrees, dependent on the sample medium, the type of fibrin plate and the kind of plasminogen activator. The influence of inhibitors in the sample and in the fibrin plate was partly abolished by the presence of 2 M KSCN in the sample. The procedure for preparing the samples as described by Astrup and Albrechtsen did not completely eliminate the inhibitory action against the added plasminogen activators. Comparison of urokinase inhibition with tissue activator inhibition by the tissue extracts as to the degree of denaturation in the Astrup and Albrechtsen procedure showed that they have much in common. Nevertheless, some differences were found which indicated the possible existence of separate urokinase and tissue activator inhibitors or of different inhibition mechanisms for these plasminogen activators.
针对样品和纤维蛋白平板中存在的纤溶酶原激活物活性测定,结合纤维蛋白平板上存在的纤溶酶抑制剂进行了重新评估。在激活物和抑制剂含量存在显著差异的组织(人肺、肝和胎盘)中研究了抑制物质的性质、作用和稳定性。对从不同等级的纤维蛋白原和纤维蛋白制备的纤维蛋白平板上的提取物,测试其对纯化的人子宫组织纤溶酶原激活物、尿激酶和纤溶酶的抑制能力。组织提取物对纤维蛋白平板上的纤维蛋白溶解有不同程度的抑制作用,这取决于样品介质、纤维蛋白平板类型和纤溶酶原激活物的种类。样品中2M KSCN的存在部分消除了样品和纤维蛋白平板中抑制剂的影响。Astrup和Albrechtsen所述的样品制备程序并未完全消除对添加的纤溶酶原激活物的抑制作用。通过Astrup和Albrechtsen程序中组织提取物对尿激酶抑制和组织激活物抑制的变性程度比较表明,它们有许多共同之处。然而,也发现了一些差异,这表明可能存在单独的尿激酶和组织激活物抑制剂,或者这些纤溶酶原激活物存在不同的抑制机制。